1. Implications of Pediatric Initiatives on CNS Drug Development for All Ages--2020 and Beyond: Second of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development.
- Author
-
PANDINA, GAHAN, BUSNER, JOAN, HORRIGAN, JOSEPH P., MCSHERRY, CHRISTINE, BATEMAN-HOUSE, ALISON, PANI, LUCA, and KANDO, JUDITH
- Subjects
CENTRAL nervous system diseases ,DRUG efficacy ,DRUG approval ,PSYCHIATRIC drugs ,GOVERNMENT regulation ,PEDIATRICS ,CONFERENCES & conventions ,INSTITUTIONAL review boards ,ETHICS committees ,DRUG laws ,RESEARCH ethics ,DRUGS ,CHILD psychopathology ,DRUG development ,CENTRAL nervous system ,MEDICAL research - Abstract
This article expands upon a session, titled "Implications of Pediatric Initiatives on CNS Drug Development for All Ages--2020 and Beyond," that was presented as part of a two-day meeting on pediatric drug development at the International Society for Central Nervous System (CNS) Clinical Trials and Methodology (ISCTM) Autumn Conference in Boston, Massachusetts, in October 2020. Speakers from various areas of pediatric drug development addressed a variety of implications of including children in drug development programs. The speakers wrote summaries of their talks, which are included here. The session's lead chair was Dr. Gahan Pandina, who wrote introductory and closing comments. Dr. Joseph Horrigan addressed the current landscape of pediatric development programs. Dr. Gahan Pandina addressed how the approach to research in pediatric populations affects the drug development process and vice versa. Dr. Alison Bateman-House discussed the ethical implications of research in the pediatric population. Dr. Luca Pani discussed some of the global regulatory issues and challenges concerning research in pediatric patients. Dr. Judith Kando served as a discussant and posed new questions about means of facilitating pediatric research. Finally, Dr. Gahan Pandina provided closing comments and tied together the presented issues. This paper should serve as an expert-informed reference to those interested and involved in CNS drug development programs that are aimed at children and/or required, through regulations, to include children as part of the approval process. [ABSTRACT FROM AUTHOR]
- Published
- 2023